May 15, 2020 / 10:41 PM / 18 days ago

BRIEF-Clovis Oncology Says Price For Rubraca In Prostate Cancer Will Align To Pricing For Ovarian Cancer Indications

May 15 (Reuters) - Clovis Oncology Inc:

* CLOVIS ONCOLOGY - PRICE FOR RUBRACA IN PROSTATE CANCER WILL ALIGN TO PRICING FOR OVARIAN CANCER INDICATIONS

* CLOVIS ONCOLOGY - DOSE FOR SPECIFIC INDICATION IS RUBRACA 600 MG TWICE DAILY AS MONOTHERAPY TREATMENT FOR PROSTATE CANCER Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below